We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

This study has been terminated.
(Lack of efficacy)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00117884
First Posted: July 11, 2005
Last Update Posted: August 19, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Takeda
  Purpose
The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.

Condition Intervention Phase
Papillomavirus Infections Drug: 851B Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-Controlled, Dose Response Study to Evaluate 851B Gel Delivered Intravaginally Twice a Week for Two, Three-Week Cycles in Women Who Are Positive For High-Risk Genotypes of Human Papillomavirus and Have Mild Cytological Abnormalities

Further study details as provided by Takeda:

Primary Outcome Measures:
  • Time to clearance of high-risk human papillomavirus infection. [ Time Frame: At each visit ]

Secondary Outcome Measures:
  • Proportion of subjects with evidence of regression to normal cytology. [ Time Frame: Screening Visit and Follow-up Visits (Months 6, 8, 14, 20, and 26). ]
  • Proportion of subjects with improvement in cervical lesions as rated by the investigator (measured by colposcopy). [ Time Frame: At each visit ]
  • Proportion of subjects who develop histological evidence of cervical intraepithelial neoplasia. [ Time Frame: Visits 1-3 as assigned by group ]
  • Time to progression of disease to precancer. [ Time Frame: Visits 1-3 as assigned by group ]
  • Change in relative light units ratios relative to the positive control from Hybrid Capture 2® assay (semi-quantitatively assessing viral load). [ Time Frame: At each visit ]

Enrollment: 240
Study Start Date: April 2006
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: 851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
Experimental: 2 Drug: 851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
Experimental: 3 Drug: 851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
Experimental: 4 Drug: 851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
Experimental: 5 Drug: 851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
Experimental: 6 Drug: 851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
Experimental: 7 Drug: 851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
Experimental: 8 Drug: 851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
Experimental: 9 Drug: 851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
Experimental: 10 Drug: 851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
Experimental: 11 Drug: 851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.

Detailed Description:

Cervical cancer is caused by infection with specific genotypes of the human papillomavirus referred to as oncogenic or high-risk human papillomavirus. Current epidemiologic evidence suggests that 80% of sexually active women will become infected during their lifetime with human papillomavirus and 50% of these infections will be due to high-risk human papillomavirus. With US annual rates of cervical cancer now in the range of 13,000/year, a very substantial number of women are left with uncertainty regarding whether their infection will clear spontaneously or progress to cancer.

Subjects participating in this study were required to visit the clinic for approximately 15 or 16 visits, and maintain a diary of self-dosing and menstruation cycles. The total time of participation in this study was approximately 27 months.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Willing to be on acceptable method of birth control
  • Have a Pap smear result of LSIL or ASCUS
  • Is high risk HPV positive

Exclusion Criteria:

  • No evidence of high-grade disease or glandular abnormalities,
  • Complete visualization of all lesion margins and the transformation zone,
  • No uncontrolled significant medical illness or sexually transmitted infections,
  • Taking any restricted medications such as interferon, immunomodulators, cytotoxic drugs, investigational drugs, steroids.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00117884


  Show 23 Study Locations
Sponsors and Collaborators
Takeda
Investigators
Study Director: Medical Director Takeda
  More Information

Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT00117884     History of Changes
Other Study ID Numbers: 1537-851B
U1111-1127-5850 ( Registry Identifier: WHO )
First Submitted: July 1, 2005
First Posted: July 11, 2005
Last Update Posted: August 19, 2016
Last Verified: August 2016

Keywords provided by Takeda:
Papillomavirus infections;
Cervix Dysplasia

Additional relevant MeSH terms:
Infection
Communicable Diseases
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Tumor Virus Infections